Covered many times over — but frozen. A 0.97% yield on a 23.32% payout is covered several times over — and it does not compound: $0.24 a quarter, $0.96 a year, at the $98.56 close on Oct. 23, 2026, the same rate paid since 2018. Management has instead directed cash to buybacks — about $500.8 million in the first half of 2026 against $93.4 million of dividends — so the dividend is safe and deliberately static.
Key risk: Procedure-volume and pricing pressure — orthopedic demand and hospital capital budgets set revenue, and a soft procedure quarter would hit the buyback-funded return story before it threatens this small dividend.
Changes if: The $0.24 rate is finally raised — that would turn this from a frozen payer into a compounding one — or free cash flow coverage narrows toward the dividend total. A raise is the upside tripwire here.
- ✓Payout-coverage check: 23.32% of trailing earnings — the $0.96 indicated dividend is covered roughly four times over by earnings, and about six times by trailing free cash flow.
- !Yield check: 0.97% indicated — $0.24/qtr × 4 at the $98.56 close on Oct. 23, 2026. Real cash, but under 1% and shrinking in real terms while the rate stands still.
- ✗Dividend growth check: No increase since 2018 — the same $0.24 a quarter declared Aug. 28, 2026 for payment Oct. 30, 2026, while buybacks ran more than five times the dividend in the first half of 2026.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.